Logo for Ipsen S.A.

Ipsen Investor Relations Material

Latest events

Logo for Ipsen S.A.

Status Update

Ipsen
Logo for Ipsen

Status Update

14 Nov, 2023
Logo for Ipsen

Q3 2023 TU

26 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Ipsen S.A. provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders and rare diseases. The company's products include Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell ad second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure and GH deficiency in adults; Increlex for growth failure in children and adolescents.